---

🫀 ACUTE MYOCARDIAL INFARCTION (AMI) — HEART ATTACK

A Complete Medical Education from Basic Science to Clinical Practice

Based on: Braunwald's Heart Disease | Robbins & Cotran Pathology | Goldman-Cecil Medicine | Ganong's Physiology | 2025 ACC/AHA ACS Guidelines

---

"Every 40 seconds, someone in the United States has a heart attack. Every minute of delay in treatment costs muscle. Time = Myocardium."

---

PART 1: CORE UNDERSTANDING

---

SECTION 1: DEFINITION

Simple Explanation (Beginner Level):

• Acute = sudden onset
• Myo = muscle
• Cardial = of the heart
• Infarction = tissue death due to lack of blood supply

Intermediate Medical Definition:

1. Symptoms of myocardial ischemia
2. New ischemic ECG changes
3. Development of pathological Q waves
4. Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality
5. Identification of a coronary thrombus by angiography or autopsy

---

SECTION 2: EPIDEMIOLOGY

The Scale of the Problem:

• Males are at higher risk through middle age - women are somewhat protected by estrogen during reproductive years
• After menopause, female risk rises sharply and IHD becomes the most common cause of death in older women
• Post-menopausal hormone replacement therapy (HRT) does not protect against MI and may be pro-thrombotic

---

SECTION 3: ETIOLOGY (CAUSES)

Simple Analogy:

Causes by Type (Universal MI Classification):

Pearl: The vast majority (~90%) of all MIs are Type 1 - caused by atherosclerotic plaque rupture.

Uncommon Causes (the 10%):

• Vasospasm (e.g., cocaine use, Prinzmetal's angina)
• Coronary embolism (from atrial fibrillation, endocarditis, prosthetic valves)
• Spontaneous Coronary Artery Dissection (SCAD) - occurs most often in peripartum women
• Vasculitis (e.g., Kawasaki disease in children)
• Severe anemia + tachycardia
• Aortic stenosis (narrowing of heart valve → inadequate coronary filling)

---

SECTION 4: RISK FACTORS

Non-Modifiable (Cannot Be Changed):

Modifiable (Can Be Changed - MOST IMPORTANT CLINICALLY):

---

SECTION 5: CLASSIFICATION / TYPES

The ACS Spectrum (Most Important Classification):

ATHEROSCLEROTIC PLAQUE RUPTURE
              ↓
    ACUTE CORONARY SYNDROME (ACS)
    ┌──────────────┬──────────────────────┐
    │              │                      │
Unstable     NSTEMI               STEMI
Angina    (Non-ST Elevation MI)  (ST Elevation MI)
    │              │                      │
No troponin    Troponin ↑          Troponin ↑↑
rise        No ST elevation     ST elevation ≥1mm
            (partial occlusion)  (complete occlusion)

• STEMI = Complete coronary occlusion → transmural (full thickness) infarction → ST elevation on ECG → EMERGENCY: open the artery within 90 minutes
• NSTEMI = Partial or transient occlusion → subendocardial infarction → no ST elevation but troponin rises → urgent but slightly less time-critical than STEMI
• Unstable Angina = Same pathology but NO troponin rise = no actual death of muscle cells yet

By Location (Which Artery is Blocked):

By Extent:

• Transmural MI: Full thickness of heart wall - classically STEMI
• Subendocardial (non-transmural) MI: Only inner layer - classically NSTEMI

---

SECTION 6: RELEVANT ANATOMY

The Coronary Circulation - Know This Like Your ABCs:

AORTA
  ↓
  ├── LEFT MAIN CORONARY ARTERY (LMCA) - "The Widow Maker"
  │     ├── LEFT ANTERIOR DESCENDING (LAD)
  │     │     → Anterior wall of LV, anterior septum, apex
  │     │     → Supplies >50% of LV muscle mass
  │     │     → LAD occlusion = MOST DANGEROUS MI
  │     │
  │     └── LEFT CIRCUMFLEX (LCx)
  │           → Lateral and posterior LV wall
  │
  └── RIGHT CORONARY ARTERY (RCA)
        → Inferior LV wall, posterior septum
        → Right ventricle
        → SA node (in 60%), AV node (in 90%)
        → RCA occlusion = inferior MI + heart block risk

• LMCA occlusion: Catastrophic - both LAD and LCx territory lost → cardiogenic shock
• LAD occlusion: Anterior STEMI - worst prognosis among the three
• RCA occlusion: Inferior STEMI - important complication is right ventricular MI and heart block (because RCA supplies the AV node in 90% of people)

---

SECTION 7: RELEVANT PHYSIOLOGY

Normal Coronary Blood Flow:

• Perfusion pressure = Diastolic blood pressure - LVEDP (Left Ventricular End-Diastolic Pressure)
• Coronary vascular resistance (the main regulator)
• Heart rate - higher HR = shorter diastole = less time for coronary filling

Critical Insight: Coronary arteries fill almost entirely during diastole (when the heart is relaxed), NOT during systole (when the heart squeezes). This is because during systole, the contracting heart muscle compresses its own vessels. So: tachycardia is dangerous in AMI because it shortens diastolic filling time, reducing coronary perfusion.

What Happens When Flow Stops:

Coronary artery occluded
         ↓
Ischemia (reversible injury) - within seconds to minutes
         ↓
ATP depletion (heart uses ATP for pumping)
         ↓
Na+/K+ pump fails → Na+, Ca2+ flood into cells
         ↓
Cell swelling, loss of contractility
         ↓
After ~20-40 minutes → IRREVERSIBLE NECROSIS begins
(the "point of no return")
         ↓
Complete infarction of full-thickness wall in 3-6 hours
         ↓
Myocyte death → scar formation

---

PART 2: PATHOPHYSIOLOGY

---

SECTION 8: DETAILED PATHOGENESIS

Step-by-Step: How a Heart Attack Develops

Endothelial injury (from hypertension, smoking, dyslipidemia, diabetes)
         ↓
LDL cholesterol enters vessel wall → oxidized LDL (oxLDL)
         ↓
Macrophages engulf oxLDL → become "Foam Cells"
         ↓
Foam cells accumulate → form "Fatty Streak" (visible as early as teenage years)
         ↓
Smooth muscle cells migrate, proliferate, secrete collagen
         ↓
"Fibrous Plaque" forms (core of lipid + necrotic debris, covered by fibrous cap)
         ↓
Calcification, neovascularization → "Complex Plaque" (Atheroma)

VULNERABLE PLAQUE (thin fibrous cap + large lipid core)
         ↓
Triggers: physical stress, mental stress, morning catecholamine surge,
          cold weather, heavy meal, hypertension spike
         ↓
PLAQUE RUPTURE or EROSION (the critical event)
         ↓
Subendothelial collagen + necrotic plaque contents exposed to blood

Exposed collagen + tissue factor activate platelets
         ↓
Platelets adhere (via GPIb-vWF interaction) → activate → aggregate
         ↓
Release: Thromboxane A2, ADP, serotonin
         ↓
Further platelet aggregation + coronary vasospasm
         ↓
Coagulation cascade activated by tissue factor
         ↓
Fibrin mesh traps red blood cells → THROMBUS
         ↓
Within minutes: complete coronary artery occlusion

This is exactly WHY aspirin (inhibits TXA2) and P2Y12 inhibitors like clopidogrel/ticagrelor (block ADP receptor) are the cornerstones of AMI treatment - they target this exact pathway.

Cellular Mechanisms:

1. ATP depletion: The heart is the highest ATP-consumer in the body. Within 60 seconds of ischemia, ATP falls to ~65% of normal. Within 10 minutes, to ~15%.
2. Na+/K+ ATPase pump failure: Without ATP, this pump stops. Na+ accumulates inside cells, water follows = cell swelling.
3. Ca2+ overload - the executioner:
   • Na+ accumulation drives Na+/Ca2+ exchanger in reverse
   • Ca2+ floods into the cell
   • Intracellular Ca2+ overload activates destructive enzymes: phospholipases, proteases, endonucleases
   • Also causes hypercontracture - irreversible contraction bands destroying cell architecture
4. Reperfusion injury paradox:
   • Opening the artery can WORSEN some cellular injury!
   • Sudden restoration of O₂ → burst of reactive oxygen species (ROS/free radicals)
   • Ca2+ paradox during reperfusion
   • This is why cardioprotective strategies during PCI are an active research area

Molecular Mechanisms - Biomarker Release:

Why troponin is the gold standard: Cardiac troponin (cTnI and cTnT) is highly specific to heart muscle. It is the most sensitive and specific marker for myocardial necrosis. Modern high-sensitivity troponin (hs-cTn) can detect elevations within 1-2 hours of symptom onset.

---

SECTION 9: GROSS AND MICROSCOPIC PATHOLOGY

Gross Changes Over Time:

Microscopic Changes:

Pathology Pearl: The scar is inert - it does NOT contract. This is why large anterior MIs cause Left Ventricular Dysfunction and Heart Failure - the scar just bulges (aneurysm) instead of contracting.

---

PART 3: CLINICAL FEATURES

---

SECTION 10: SYMPTOMS

Typical Presentation: "OPQRST" of Chest Pain

Associated Symptoms - The "Accompanying Features":

• Diaphoresis (profuse sweating) - due to sympathetic nervous system activation
• Dyspnea (shortness of breath) - due to rising left ventricular filling pressure → pulmonary edema
• Nausea and vomiting - due to activation of vagal reflexes (especially in inferior MI, which is close to the diaphragm)
• Palpitations - due to arrhythmias (very common)
• Lightheadedness/Syncope - due to low cardiac output or arrhythmia
• Sense of impending doom ("angor animi") - a classical and important feature

Why Each Symptom Occurs - Mechanism Explained:

---

SECTION 11: ATYPICAL PRESENTATIONS

"The MI that doesn't tell you it's coming." This is where doctors miss diagnoses and patients die.

High-Risk Groups for Atypical Presentations:

Clinical Pearl: Up to 25-30% of all MIs are "silent" (detected only on routine ECG). Diabetics and elderly patients are most at risk. Always have a low threshold to get an ECG in these groups presenting with any cardiac-sounding complaint.

---

SECTION 12: SIGNS ON EXAMINATION

General Examination:

Cardiovascular Examination:

Respiratory Examination:

• Bilateral basal crackles: Pulmonary edema from left heart failure
• Wheeze ("cardiac asthma"): Bronchospasm from pulmonary congestion

Killip Classification (Based on Examination):

---

SECTION 13: TYPICAL PATIENT PRESENTATION

Clinical Scenario - The Classic Patient:

"A 58-year-old male smoker with known diabetes and hypertension wakes up at 6:30 AM with severe crushing central chest pain radiating to his left arm and jaw, 9/10 severity. Associated with profuse sweating and feeling of impending doom. Pain has not been relieved by lying down or two antacids. He is pale, sweaty, HR 102, BP 148/92, RR 20. He has diaphoresis. On auscultation, an S4 gallop is heard. ECG shows 3mm ST elevation in V1-V4."

---

PART 4: HISTORY TAKING

---

SECTION 14: THE AMI HISTORY - What to Ask and Why

Chief Complaints to Document:

1. Chest pain/tightness/heaviness
2. Shortness of breath
3. Palpitations
4. Sweating
5. Nausea/vomiting
6. Syncope

History of Present Illness - KEY QUESTIONS:

Past Medical History:

• Previous MI, CABG, PCI, stent? - May alter ECG interpretation; stent thrombosis possible
• Previous angina? - Nature of change in pattern (stable → unstable)
• Hypertension, Diabetes, Dyslipidemia? - Key risk factors
• CKD? - Affects dosing of contrast, medications
• Bleeding disorders, recent surgery? - Contraindications to thrombolysis/anticoagulation

Drug History - CRITICAL for AMI Management:

Family History:

• Premature CAD (father <55, mother <65) = major independent risk factor
• Familial Hypercholesterolemia (very high LDL from birth)
• Sudden cardiac death in family

Personal/Social History:

• Smoking (current/ex; pack-years)
• Alcohol consumption
• Cocaine, amphetamines (young patient with MI → always ask)
• Stress (job, marital, financial)
• Exercise habits, diet
• Occupation (heavy labor + cardiac stress)

---

PART 5: DIFFERENTIAL DIAGNOSIS

---

SECTION 15: DIFFERENTIAL DIAGNOSES

Rule #1: Never rush to diagnose chest pain. Several life-threatening conditions mimic AMI. STEMI mimics exist - treat appropriately only after confirmation.

The Dangerous Chest Pain Differentials - Comparison Table:

STEMI Mimics - Critically Important:

Never give thrombolysis without excluding aortic dissection! (dissection can extend to coronary ostium causing STEMI-like picture; lysing the clot in a dissection can be FATAL)

• Left Bundle Branch Block (LBBB) - new LBBB in context of symptoms = treat as STEMI
• Left Ventricular Hypertrophy (Sokolow-Lyon pattern)
• Early repolarization (benign normal variant - seen in young men; J-point elevation)
• Brugada pattern (V1-V2 ST coved elevation - arrhythmia syndrome)
• Hyperkalemia (peaked T waves + wide QRS)
• Pericarditis (diffuse saddle-shaped elevation)

---

PART 6: INVESTIGATIONS

---

SECTION 16: BASIC INVESTIGATIONS

Bedside/Point-of-Care (First 10 Minutes):

ECG
↓
What it measures → Electrical activity of heart across 12 perspectives (leads)
↓
Why ordered → Changes in ischemia and infarction are rapid and specific
↓
Expected findings in STEMI:
  - ST elevation ≥1mm in ≥2 contiguous limb leads
  - ST elevation ≥2mm in ≥2 contiguous chest leads
  - New LBBB in right clinical context
↓
Expected findings in NSTEMI/UA:
  - ST depression (horizontal or downsloping ≥0.5mm)
  - T wave inversions
  - Normal ECG (does NOT exclude MI!)

ECG Evolution in STEMI (Learn This Timeline):

Emergency Instruction: In suspected inferior STEMI, ALWAYS place right-sided leads (V3R-V4R) to detect RV infarction. RV infarction changes management completely - these patients are preload dependent (need IV fluids) and nitrates are relatively contraindicated (can cause fatal hypotension).

---

SECTION 17: SPECIFIC INVESTIGATIONS (BLOOD TESTS)

Cardiac Biomarkers - The Diagnostic Foundation:

Troponin I/T
↓
What it measures → Troponin is a protein that anchors actin-myosin in myocytes.
                   Released into blood when myocytes die.
↓
Why ordered → Most sensitive + specific marker for myocardial necrosis
↓
Expected findings:
  - Normal: <99th percentile URL (lab-specific; usually <0.03-0.04 ng/mL)
  - MI: Rise AND fall pattern (peak > 99th percentile)
  - A single elevated troponin is NOT diagnostic - need rise AND fall
  - hs-cTn 0/1-hour or 0/2-hour algorithm (serial measurements 1-2 hours apart)
↓
Interpret with caution in: CKD, PE, myocarditis, heart failure, sepsis
  (these cause "troponin leak" without plaque rupture)

• hs-cTnT at 0 hours AND 1 hour
• If 0h <5 ng/L (very low) AND Δ 0→1h <3 ng/L → Rule OUT AMI with 99.5% sensitivity
• If 0h ≥52 ng/L OR Δ 0→1h ≥5 ng/L → Rule IN AMI
• All others → continue observation to 3h

Routine Blood Tests:

---

SECTION 18: IMAGING

1. Chest X-Ray (CXR):

CXR in AMI
↓
What it shows → Cardiac silhouette, pulmonary vasculature, mediastinum
↓
Expected findings:
  - Normal (early, uncomplicated MI)
  - Cardiomegaly (previous LV dysfunction)
  - Pulmonary venous congestion → bilateral perihilar haziness ("bat's wing")
  - Pleural effusions (bilateral basal)
  - "Upper lobe diversion" (vessels engorged at upper lobes = early pulmonary hypertension)
  - Widened mediastinum → EXCLUDE AORTIC DISSECTION first!

2. Echocardiogram (Echo) - 2D + Doppler:

"The cardiologist's stethoscope" - Echo provides real-time information no blood test can.

Echo
↓
What it shows → Heart wall motion, valve function, pericardium, ejection fraction
↓
Why ordered:
  - Assess LV function (Ejection Fraction - EF)
  - Regional Wall Motion Abnormality (RWMA) = tells you which territory is infarcted
  - Detect mechanical complications (VSD, papillary muscle rupture, free wall rupture)
  - Assess RV function (important in inferior MI)
  - Detect pericardial effusion
↓
Expected findings:
  - RWMA corresponding to infarct territory (hypokinesis → akinesis → dyskinesis)
  - EF <40% = significant LV dysfunction = start ACEI/ARB
  - New mitral regurgitation jet = papillary muscle involvement
  - VSD visible as turbulent flow between ventricles = emergency surgery

Ejection Fraction (EF): The percentage of blood the left ventricle pumps out with each beat. Normal = 55-70%. Post-MI EF <40% = Heart Failure with Reduced EF (HFrEF) - requires ACEI, beta-blocker, aldosterone antagonist.

3. Coronary Angiography (The Gold Standard for CAD):

Coronary Angiography
↓
What it does → Injects contrast dye into coronary arteries while X-raying the heart
↓
Why done → Identifies EXACT location and severity of blockage; guides PCI
↓
Findings in STEMI → Complete occlusion ("TIMI 0 flow") of culprit artery
Findings in NSTEMI → Tight stenosis ("TIMI 1-2 flow") or no occlusion
↓
Simultaneously with PCI in STEMI (diagnostic + therapeutic in one procedure)

---

PART 7: DIAGNOSIS

---

SECTION 19: DIAGNOSTIC CRITERIA

4th Universal Definition of MI (ESC/ACC/AHA 2018):

1. Symptoms of acute myocardial ischemia
2. New ischemic ECG changes
3. Development of pathological Q waves
4. New loss of viable myocardium or regional wall motion abnormality on imaging
5. Coronary thrombus on angiography or autopsy

Diagnostic Algorithm:

Patient with chest pain
         ↓
         ├── ECG → ST ELEVATION in ≥2 contiguous leads?
         │              YES → STEMI → Immediate PCI activation
         │              NO  ↓
         │
         ├── hs-Troponin 0h and 1h (or 0h and 3h)
         │              ↑ with rise/fall pattern → NSTEMI
         │              Normal + ↓ serial → Rule out MI / consider UA
         │
         └── In doubt → Echo (RWMA?), repeat ECG, clinical reassessment

---

SECTION 20: RISK SCORING SYSTEMS

TIMI Risk Score for NSTEMI/UA (The Clinical Score):

TIMI = Thrombolysis in Myocardial Infarction (name of the original research group that validated this score)

• 0-2 = Low risk: 4-8% 14-day event rate
• 3-4 = Intermediate: 13-19%
• 5-7 = High risk: 25-41% → urgent angiography

GRACE Score (Global Registry of Acute Coronary Events):

• GRACE ≥140 = High risk → invasive strategy within 24h
• GRACE <109 = Low risk → can do elective angiography

---

PART 8: COMPLICATIONS

---

SECTION 21: COMPLICATIONS OF AMI

Mnemonic: "DARTH VADER" for AMI complications:

Acute Complications (First 24-72 hours):

"Reperfusion arrhythmia" - The appearance of AIVR after thrombolysis or PCI is actually a GOOD SIGN - it means the artery has opened. Don't panic and treat it.

• Definition: Systolic BP <90 mmHg for >30 min + signs of tissue hypoperfusion (cold clammy extremities, oliguria, altered consciousness)
• Mechanism: Loss of >40% of LV mass → pump failure
• Mortality: 40-50% even with optimal treatment
• Management: Inotropes (dobutamine, norepinephrine) + urgent PCI + consider Impella or IABP (2025 AHA now recommends microaxial flow pump - Impella for select patients)

Mechanical Complications (Days 3-7 - Peak Soft Tissue Risk):

• Timing: 3-7 days post-MI (when myocardium is softest)
• Presentation: Sudden collapse → pericardial tamponade → electromechanical dissociation (EMD/PEA arrest)
• Risk: Large transmural MI, elderly, female, first MI, no prior angina, delayed reperfusion
• Management: Emergency pericardiocentesis + surgical repair; extremely high mortality

• Timing: Days 3-7
• Presentation: Sudden new loud pansystolic murmur at lower sternal border + acute hemodynamic deterioration
• Mechanism: Necrosis of interventricular septum → rupture → left-to-right shunt
• Diagnosis: Echo (color flow Doppler shows flow through septum)
• Management: Surgical repair (emergency) or transcatheter closure; very high operative mortality but surgery still best option

• Timing: Days 2-7
• Presentation: Sudden new pansystolic murmur at apex + acute pulmonary edema
• Important: Posteromedial papillary muscle is more vulnerable (supplied by single artery - RCA; anterolateral gets dual supply)
• Diagnosis: Echo (severe MR, flail leaflet, papillary muscle dysfunction)
• Management: Emergency mitral valve surgery; bridge with IABP

Subacute/Late Complications:

• Early (Epistenocardiac pericarditis): Days 1-3; due to necrosis irritating adjacent pericardium; short-lived; treat with aspirin
• Late (Dressler's Syndrome): 2-6 weeks post-MI; immune-mediated; fever + pleuropericarditis + ↑ ESR + ↑ CRP; treat with aspirin/NSAIDs/colchicine

• Timing: Weeks-months after large anterior MI
• Mechanism: Infarcted thin scar bulges outward (dyskinesis) → true aneurysm
• Presentation: Persistent ST elevation (weeks after MI), CHF, thrombus formation, arrhythmia
• Diagnosis: Echo (dyskinetic segment), CXR (bulge), Left ventriculogram
• Management: Anticoagulation for thrombus, ACEI, diuretics; surgery if refractory

• Risk: Apex of LV (poor flow in akinetic area); especially with anterior MI
• Complication: Systemic embolism → stroke
• Diagnosis: Echo; cardiac MRI more sensitive
• Management: Anticoagulation with warfarin (INR 2-3) for 3-6 months

• Chronic complication: Loss of functional myocardium → chronic pump failure
• Requires: ACEI/ARB, beta-blocker, aldosterone antagonist, SGLT2 inhibitor (per 2024 HF guidelines)

---

PART 9: EMERGENCY MEDICINE

---

SECTION 22: RED FLAGS AND EMERGENCY MANAGEMENT

Absolute Red Flags - Never Miss These:

WHEN TO ADMIT:

• ALL suspected STEMI → direct to cath lab (or thrombolysis then transfer)
• ALL confirmed NSTEMI → admit to cardiac care unit (CCU)
• High TIMI/GRACE score
• Any hemodynamic instability
• Arrhythmias detected
• Any ECG change from baseline
• Persistent pain despite initial treatment

ICU/CCU INDICATIONS:

• Cardiogenic shock
• Malignant arrhythmias (VT/VF, complete heart block)
• Respiratory failure requiring ventilation
• Post-cardiac arrest resuscitation
• Mechanical complications requiring urgent intervention

---

PART 10: MANAGEMENT

---

SECTION 23: TREATMENT GOALS

1. Immediate: Restore coronary blood flow (time = myocardium)
2. Short-term: Limit infarct size, prevent complications, manage arrhythmias
3. Medium-term: Preserve LV function, prevent remodeling
4. Long-term: Prevent recurrent MI (secondary prevention), treat risk factors

The "MONA BASH" Framework for Initial Treatment:

MONA BASH (commonly taught mnemonic, though some components are now evidence-refined):

• Morphine - use cautiously (may delay antiplatelet absorption - see below)
• Oxygen - only if SpO₂ <90%
• Nitrates - sublingual GTN (NOT if SBP <90, RV infarction, or Viagra use)
• Aspirin - 300mg loading dose immediately
• Beta-blockers - within 24h (oral, not IV in acute setting unless specific indication)
• Anticoagulants - heparin (UFH or LMWH)
• Statins - high-intensity atorvastatin 80mg immediately
• P2Y12 inhibitor - clopidogrel/ticagrelor/prasugrel loading dose

2025 ACC/AHA Update: Morphine use with P2Y12 inhibitors should be avoided if possible - morphine slows gastric emptying, reducing absorption of oral antiplatelets. Use for refractory pain only.

---

SECTION 24: REPERFUSION STRATEGIES (THE MOST CRITICAL TREATMENT)

The core of STEMI treatment: Open the blocked artery as fast as possible. Every minute of delay destroys more muscle.

Strategy 1: Primary PCI (Percutaneous Coronary Intervention) - PREFERRED

• Door-to-Balloon time ≤90 minutes (from arrival at PCI-capable hospital to balloon inflation)
• If transferred from non-PCI center: total first medical contact-to-balloon ≤120 minutes

1. Radial artery access preferred over femoral (reduces bleeding complications, vascular complications, and death)
2. Intravascular imaging (IVUS or OCT) to guide PCI is now a Class I recommendation (previously Class IIa) - improves stent deployment accuracy
3. Complete revascularization recommended (treat non-infarct arteries too, either during primary PCI or staged within 45 days) - improves outcomes in STEMI/NSTEMI

Strategy 2: Fibrinolysis (Thrombolysis) - When PCI Not Available:

• Any prior intracranial hemorrhage
• Known structural cerebral vascular lesion (AVM, aneurysm)
• Known intracranial malignancy
• Ischemic stroke within 3 months
• Suspected aortic dissection ← this is why you MUST exclude dissection first
• Active bleeding or bleeding diathesis
• Significant closed head trauma/facial trauma within 3 months
• Intracranial or intraspinal surgery within 2 months

• Transfer to PCI-capable center for "pharmaco-invasive strategy" (coronary angiography within 3-24 hours even if lysis appears successful)
• Signs of failed reperfusion (ST still elevated after 90 min) → rescue PCI immediately

---

PART 11: PHARMACOLOGY

---

SECTION 25: DRUG-BY-DRUG BREAKDOWN

DRUG 1: ASPIRIN (Acetylsalicylic Acid)

Drug: Aspirin
Drug Class: Antiplatelet agent / COX-1 inhibitor
↓
Mechanism: Irreversibly inhibits cyclooxygenase (COX)-1 enzyme in platelets
           → blocks synthesis of Thromboxane A2 (TXA2)
           → TXA2 normally causes platelet aggregation + vasoconstriction
           → Without TXA2, platelets cannot aggregate as effectively
           → Effect lasts LIFETIME of the platelet (~7-10 days, as platelets
              cannot make new COX-1)
↓
Why used in AMI: Prevents further platelet aggregation on the ruptured plaque
                 and growing thrombus
↓
Expected Benefit: Reduces mortality by ~23% in acute MI (ISIS-2 trial)
↓
Adult Dose (AMI): 300mg (or 325mg) chewed loading dose immediately
                  Then: 75-100mg daily (maintenance, lifelong)
↓
Pediatric Dose: Not routinely used in children; if needed, 10-15mg/kg
↓
Route: Oral (chewed, not swallowed whole - for faster absorption)
↓
Side Effects:
  - GI irritation/ulcers (use PPI if high GI risk)
  - Bleeding
  - Reye's syndrome (in children with viral illness - avoid in <16 years)
  - Aspirin-exacerbated respiratory disease (in some asthmatics)
↓
Contraindications: Active GI bleeding, known hypersensitivity, severe hepatic failure
↓
Drug Interactions: Increases bleeding risk with anticoagulants, NSAIDs, SSRIs
↓
Pregnancy: Avoid in 3rd trimester (Category C/D); low-dose may be used in some conditions
↓
Important Prescribing Note: NEVER omit aspirin in STEMI. It saves lives.

---

DRUG 2: TICAGRELOR (Preferred) / CLOPIDOGREL / PRASUGREL - P2Y12 INHIBITORS

P2Y12 receptor: ADP (Adenosine Di-Phosphate) receptor on platelets. When ADP binds P2Y12, platelets activate and aggregate. P2Y12 inhibitors block this receptor.

2025 AHA Guideline: DAPT (Dual Antiplatelet Therapy = Aspirin + P2Y12 inhibitor) for 12 months is standard after MI. Patients with high bleeding risk may be de-escalated to 6 months or DAPT modification strategies. Patients with high thrombotic risk (complex PCI, recurrent events) may benefit from extended DAPT or adding rivaroxaban 2.5mg BID.

---

DRUG 3: HEPARIN (Anticoagulant)

---

DRUG 4: STATINS (High-Intensity)

Mechanism: HMG-CoA reductase inhibitor
           → Blocks cholesterol synthesis in liver
           → Liver compensates by upregulating LDL receptors
           → More LDL cleared from blood
           → Plaque stabilization (immediate, pleiotropic effect - independent of LDL lowering)
↓
Why used immediately in AMI (even before LDL result):
  - Plaque stabilization (reduces risk of re-rupture)
  - Anti-inflammatory
  - Reduces 30-day mortality
↓
Dose: Atorvastatin 80mg once daily (start SAME DAY as admission)
      Rosuvastatin 40mg once daily (alternative)
↓
Target LDL: <55 mg/dL (1.4 mmol/L) for very high cardiovascular risk (post-MI)
↓
Side Effects:
  - Myalgia (muscle aching) - most common
  - Myositis, rhabdomyolysis (rare but serious - check CK if severe muscle pain)
  - Hepatotoxicity (rare - check LFTs at baseline)
  - Diabetes risk (modest; benefits far outweigh risk in AMI)
↓
Drug Interactions: Cyclosporine, gemfibrozil, clarithromycin, azole antifungals (↑ statin levels)
↓
Contraindications: Active liver disease, pregnancy, breastfeeding

---

DRUG 5: BETA-BLOCKERS

Mechanism: Block β1-adrenergic receptors on:
           - Heart: ↓ Heart rate (negative chronotropy)
                    ↓ Contractility (negative inotropy)
                    ↓ Conduction velocity (negative dromotropy)
           → Overall: ↓ Myocardial oxygen demand
↓
Why used in AMI:
  - ↓ Infarct size (by reducing O₂ demand)
  - ↓ Arrhythmias (especially VF in acute phase)
  - ↓ Mortality (proven in multiple RCTs)
  - ↓ Myocardial remodeling (long-term benefit)
↓
Timing: START ORALLY within first 24 hours if no contraindications
        IV beta-blockers: ONLY if hypertension + tachycardia + NO heart failure/shock
↓
Dose:
  - Metoprolol tartrate: 25-50mg oral BD (titrate up)
  - Carvedilol: 3.125mg BD (titrate up to 25mg BD over weeks)
  - Bisoprolol: 1.25mg-10mg once daily
↓
Contraindications (ABSOLUTE in acute setting):
  - Acute heart failure (Killip III-IV)
  - Cardiogenic shock
  - Significant bradycardia (HR <60)
  - Heart block (2nd/3rd degree without pacemaker)
  - Severe bronchospastic asthma
↓
Side Effects: Bradycardia, hypotension, fatigue, cold extremities, bronchospasm
              Mask hypoglycemia symptoms in diabetics
↓
Long-term: Continue indefinitely post-MI (especially if EF <40%)

---

DRUG 6: ACE INHIBITORS (ACEi) / ARBs

Mechanism (ACEi):
  ACE inhibitors block the enzyme that converts Angiotensin I → Angiotensin II
  Angiotensin II normally:
    - Causes vasoconstriction
    - Stimulates aldosterone release (salt and water retention)
    - Promotes cardiac remodeling (scar enlargement) after MI
  By blocking ACE:
    - Vasodilation → ↓ afterload (makes it easier for heart to pump)
    - ↓ Aldosterone → less salt/water retention
    - ↓ Ventricular remodeling → prevents heart failure progression
↓
Why used in AMI:
  - START within 24 hours in ALL patients with STEMI
  - Especially critical if: EF <40%, anterior MI, heart failure, hypertension, DM
  - Reduces mortality by ~7-8% in randomized trials
↓
Dose (Ramipril): 2.5mg BD (first day) → 5mg BD → 10mg once daily (target dose)
↓
ARBs used if: ACEi causes intolerable dry cough (10% of patients) or angioedema
              Valsartan 40mg BD → titrate to 160mg BD
↓
Contraindications:
  - Bilateral renal artery stenosis
  - Pregnancy (Category D - teratogenic in 2nd/3rd trimester)
  - Hyperkalemia (K+ >5.5 mmol/L)
  - Anuria, severe CKD (eGFR <30) - use with caution
  - Angioedema (ACEi) - switch to ARB
↓
Monitoring: Renal function + potassium at 1 week, 1 month, then 6-monthly

---

DRUG 7: ALDOSTERONE ANTAGONISTS (Mineralocorticoid Receptor Antagonists - MRA)

Mechanism: Block aldosterone receptors in kidney collecting duct
           → ↓ Sodium retention → ↓ Potassium loss
           → ↓ Cardiac fibrosis and remodeling
↓
Indication in AMI (per AHA 2025):
  - LV dysfunction post-MI (EF <40%)
  - AND already on ACEi/ARB + beta-blocker
  - AND either symptoms of heart failure OR diabetes
↓
Dose: Eplerenone 25mg daily → increase to 50mg daily after 4 weeks
      (if K+ <5.0 and eGFR >30)
↓
Key Danger: HYPERKALEMIA (especially with ACEi + MRA combination)
↓
Contraindications: K+ >5.0 mmol/L, eGFR <30, concurrent use of potassium-sparing diuretics

---

DRUG 8: NITRATES

Mechanism: Donates nitric oxide (NO)
           NO → activates guanylate cyclase → ↑ cGMP → smooth muscle relaxation
           → Venodilation (reduces preload = filling pressure)
           → Arterial dilation (reduces afterload)
           → Coronary vasodilation (opens collaterals)
           → Reduces myocardial oxygen demand
↓
Use in AMI:
  - SYMPTOM RELIEF: 0.4mg sublingual spray/tablet every 5 minutes × 3 doses
  - IV nitrates for persistent pain, hypertension, or pulmonary edema
↓
ABSOLUTE CONTRAINDICATIONS:
  1. SBP <90 mmHg (hypotension → dangerous drop in BP)
  2. Right Ventricular infarction (RV relies on preload; venodilation → catastrophic ↓ CO)
  3. Use of PDE-5 inhibitors in last 24-48 hours (sildenafil, tadalafil, vardenafil)
     → Both drugs drop BP; combination = potentially fatal hypotension
↓
IV Infusion: 10-200 mcg/min (titrate to pain relief, keep SBP >90)
Side Effects: Headache (very common - histamine release), flushing, hypotension, tachycardia
Tolerance: Develops with continuous infusion; provide 8-12h nitrate-free interval

---

SECTION 26: DRUG COMPARISON TABLE

---

PART 12: TREATMENT ALGORITHMS

---

SECTION 27: STEPWISE MANAGEMENT

STEMI Management Algorithm (2025 ACC/AHA):

PATIENT PRESENTS WITH CHEST PAIN
                ↓
ECG WITHIN 10 MINUTES OF ARRIVAL
                ↓
ST ELEVATION ≥1mm in ≥2 contiguous leads?
                ↓
     YES → STEMI CONFIRMED
                ↓
IMMEDIATE ACTIONS (simultaneously):
  ✓ Aspirin 300mg chewed
  ✓ Ticagrelor 180mg (or clopidogrel 600mg if ticagrelor unavailable)
  ✓ Anticoagulation: UFH 60u/kg IV bolus (max 4000U)
  ✓ Oxygen ONLY if SpO₂ <90%
  ✓ GTN sublingual (if no contraindications)
  ✓ IV access × 2, bloods drawn
  ✓ Atorvastatin 80mg
  ✓ ECG monitors + defibrillator ready
                ↓
REPERFUSION STRATEGY DECISION:
                ↓
PCI-capable hospital ─── YES → Primary PCI ─── Target: Door-to-Balloon ≤90 min
available within 120 min?         Use radial approach (Class I)
                                  Intravascular imaging (IVUS/OCT) - Class I
                                  Complete revascularization - Class I
                ↓
              NO
                ↓
FIBRINOLYSIS (if no contraindications):
  ✓ Door-to-needle ≤30 minutes
  ✓ Tenecteplase (weight-based) single bolus, OR
  ✓ Alteplase (accelerated), OR
  ✓ Streptokinase
                ↓
AFTER FIBRINOLYSIS:
  Transfer to PCI center for angiography within 3-24 hours
  If ST fails to fall ≥50% at 90 min → RESCUE PCI immediately

---

NSTEMI/UA Management Algorithm:

NSTEMI CONFIRMED (Troponin rise + no ST elevation)
                ↓
RISK STRATIFICATION:
  Calculate GRACE score or TIMI score
                ↓
┌───────────────────┬────────────────────┬──────────────────────┐
│   VERY HIGH RISK  │     HIGH RISK      │      LOW RISK        │
│  (hemodynamic     │  (GRACE ≥140 or    │  (GRACE <109,        │
│   instability,    │   TIMI ≥3)         │   TIMI 0-2)          │
│   cardiogenic     │                    │                       │
│   shock, VT/VF)   │                    │                       │
└─────────┬─────────┴──────────┬─────────┴──────────┬───────────┘
          ↓                    ↓                     ↓
   IMMEDIATE (<2h)       EARLY (<24h)          SELECTIVE
   Angiography           Angiography        Angiography/
   + PCI                 + PCI              Conservative Rx
          ↓
ALL PATIENTS receive:
  ✓ Aspirin 300mg → 75mg daily
  ✓ Ticagrelor 180mg → 90mg BD (preferred) or Clopidogrel 600mg → 75mg daily
  ✓ Anticoagulation: Enoxaparin 1mg/kg SC BD (or UFH)
  ✓ Atorvastatin 80mg
  ✓ Beta-blocker (if no contraindications)
  ✓ ACEi (within 24h if EF <40% or HF or DM)
  ✓ GTN for pain (if no contraindications)

---

PART 13: REAL-WORLD CLINICAL PRACTICE

---

SECTION 28: HOW A SENIOR DOCTOR THINKS

First Impression (The 30-Second Assessment):

1. Is he talking to me comfortably, or struggling to breathe? (Dyspnea = LV failure)
2. Is he pale and clammy? (Cardiogenic shock?)
3. What is his heart rate and blood pressure? (Tachycardia/hypotension = alarm bells)

Clinical Reasoning Framework:

"What should I think next?"

Middle-aged patient + chest pain
        ↓
Rule out life-threatening: STEMI, Dissection, Tension pneumo, PE
        ↓
ECG: ST elevation? → Activate cath lab NOW (don't wait for troponin)
ECG: No ST elevation + risk factors → Serial troponins + close monitoring
        ↓
ST elevation → "Which territory? Which artery?"
  V1-V4 = Anterior = LAD = Most dangerous
  II, III, aVF = Inferior = RCA
    → If inferior: DO right-sided leads NOW (RV infarct?)
        ↓
Inferior MI with hypotension + bradycardia → Think RV infarction
  Management change: Give IV fluids (500mL NS), avoid nitrates!
        ↓
New murmur post-MI → Think mechanical complication:
  Pansystolic at apex → papillary muscle rupture → echo STAT
  Pansystolic at lower sternal border → VSD → echo STAT

Common Mistakes to Avoid:

---

PART 14: SAMPLE PRESCRIPTIONS

---

SECTION 29: PRESCRIPTION WRITING

Sample Prescription: STEMI (Acute Phase - CCU Admission)

Name: Mr. [X], 58M | Ward: Cardiac Care Unit
Date: [today]
Diagnosis: Acute Anterior STEMI (in transit to cath lab)

1. Aspirin 300mg oral STAT (chewed) → then 75mg daily
   Rationale: Immediate antiplatelet loading

2. Ticagrelor 180mg oral STAT → then 90mg twice daily
   Rationale: P2Y12 inhibition (preferred over clopidogrel)

3. Enoxaparin 40mg SC STAT (weight-adjusted 1mg/kg)
   [OR: UFH 60 units/kg IV bolus if going directly to cath lab]
   Rationale: Prevent thrombus propagation

4. Atorvastatin 80mg oral STAT → continue daily
   Rationale: Plaque stabilization, lipid lowering

5. GTN 0.4mg sublingual PRN for chest pain (every 5 min × 3 doses)
   [Hold if SBP <90 or HR <60]
   Rationale: Symptom relief + coronary vasodilation

6. Morphine 2-4mg IV PRN if pain uncontrolled by above
   [Caution: use only if needed; delays P2Y12 absorption]

7. O₂ via nasal cannula 2-4L/min ONLY if SpO₂ <90%

POST-PCI ADDITIONS:
8. Metoprolol tartrate 25mg oral BD → titrate to 50mg BD
   [Start within 24h if HR >60, SBP >100, no acute HF]
   Rationale: Anti-arrhythmic, cardioprotective

9. Ramipril 2.5mg oral BD → titrate to 10mg daily
   [Start within 24h; check renal function and K+ at day 3]
   Rationale: Anti-remodeling, anti-heart failure

10. Pantoprazole 40mg oral daily (GI protection with DAPT)

MONITORING:
- Cardiac monitor (continuous ECG) + defibrillator at bedside
- Hourly BP, HR, SpO₂, urine output
- Troponin at 0h, 1h, 6h, 12h
- ECG 1 hour post-PCI, 6h, next morning
- Renal panel + K+ at Day 1, Day 3

---

Sample Prescription: NSTEMI (Moderate Risk - Ward)

Diagnosis: NSTEMI (GRACE score 112 = high risk, planned early angio <24h)

1. Aspirin 300mg oral STAT → 75mg daily (lifelong)
2. Ticagrelor 180mg oral STAT → 90mg twice daily × 12 months
3. Enoxaparin 1mg/kg SC BD (dose-adjusted for eGFR)
4. Atorvastatin 80mg oral nightly (high-intensity statin)
5. Metoprolol 25mg oral BD (if HR/BP permits)
6. Ramipril 2.5mg oral BD (if EF <40% or DM or HF signs)
7. GTN sublingual 0.4mg PRN
8. Pantoprazole 40mg daily

Investigations to complete:
- Echo within 24h (assess EF, RWMA)
- Coronary angiography <24h
- Fasting lipid profile, HbA1c, TFTs
- Daily ECG

---

PART 15: PREVENTION

---

SECTION 30: PRIMARY, SECONDARY, TERTIARY PREVENTION

Primary Prevention (Preventing the First MI):

Secondary Prevention (After First MI - LIFELONG):

Cardiac Rehabilitation (2025 ACC/AHA - Class I Recommendation):

After MI, ALL patients should be referred to cardiac rehabilitation (or home-based alternatives). This combines supervised exercise, education, psychological support, and risk factor modification. It reduces mortality by 20-30% post-MI.

Tertiary Prevention (Preventing Disability and Progression):

• ICD (Implantable Cardioverter Defibrillator) if EF <35% despite optimal medical therapy for ≥3 months post-MI
• CRT (Cardiac Resynchronization Therapy) if EF ≤35% + LBBB + NYHA III-IV
• Heart failure clinic follow-up with uptitration of medications
• Psychosocial support (depression is extremely common post-MI; treat it)

---

PART 16: PROGNOSIS

---

SECTION 31: PROGNOSIS

Short-Term Mortality:

• Overall 30-day mortality with modern PCI: ~5-8% (STEMI), 3-5% (NSTEMI)
• In-hospital mortality without reperfusion: ~15-30%
• Cardiogenic shock mortality: 40-50% even with optimal care

Factors Worsening Prognosis:

Long-Term Outcomes:

• With optimal secondary prevention: 5-year survival >85-90%
• Risk of recurrent MI: ~10% in 5 years (higher if undertreated)
• Heart failure develops in ~20% of STEMI survivors at 5 years
• Sudden cardiac death risk: Reduced by beta-blockers and ICD if indicated

---

PART 17: PATIENT COUNSELING

---

SECTION 32: COUNSELING THE PATIENT AND FAMILY

How to Explain the Disease (Simple Language):

"Your heart is a muscle that needs blood to work. Like all organs in the body, it gets its blood supply from special blood vessels wrapped around it, called coronary arteries. Over the years, a buildup of fatty deposits - called plaque - formed inside one of these arteries. Recently, that plaque cracked open. Your body tried to repair it by forming a clot, but the clot ended up blocking the artery completely. Without blood flow, part of your heart muscle was starved of oxygen and became damaged. We call this a heart attack, or medically, a myocardial infarction."

"We have opened that blockage with a procedure called an angioplasty and placed a tiny metal tube called a stent to keep the artery open. But now we need to make sure this never happens again."

Medications - Counseling Points:

1. Aspirin and Ticagrelor are CRITICAL - "Do not stop these tablets without telling your heart doctor. Stopping them suddenly can cause another heart attack, especially if you have a stent."
2. Statin - "This is for your cholesterol, but also for your heart health after a heart attack. You need to take this every night for life."
3. Beta-blocker - "This protects your heart by slowing it down. Don't stop suddenly."
4. ACE inhibitor - "This reduces the strain on your heart. You may have a dry cough - if so, tell us and we can switch to a different tablet."

Lifestyle Advice:

Warning Signs to Return IMMEDIATELY:

"Call emergency services (999/112/911) immediately if you experience:

• Chest pain lasting more than 5 minutes
• Severe shortness of breath
• Fainting or blackout
• Rapid pounding heartbeat
• Do NOT drive yourself - call an ambulance"

Follow-Up Advice:

---

FINAL SUMMARY - THE MASTER TABLE

---

Recent Evidence Alert (PubMed 2024-2025):

• [PMID 38986670] - Systematic review in JACC (2024): Confirms benefit of complete vs. culprit-only PCI in MI - supports the 2025 Class I recommendation for complete revascularization
• [PMID 39779054] - Network meta-analysis in JACC (2025): Optimal strategy for complete revascularization in STEMI + multivessel disease - staged PCI within 45 days appears safest
• [PMID 41223860] - Individual patient data meta-analysis in Lancet (2025): Confirms complete revascularization reduces cardiovascular death and recurrent MI vs. culprit-only

---